<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous studies have demonstrated the interaction between the Epstein-Barr virus (EBV) nuclear antigen 3C (EBNA3C) and the metastatic suppressor Nm23-H1 both in vitro and in vivo (C </plain></SENT>
<SENT sid="1" pm="."><plain>Subramanian, M </plain></SENT>
<SENT sid="2" pm="."><plain>A </plain></SENT>
<SENT sid="3" pm="."><plain>Cotter II, and E </plain></SENT>
<SENT sid="4" pm="."><plain>S </plain></SENT>
<SENT sid="5" pm="."><plain>Robertson, Nat </plain></SENT>
<SENT sid="6" pm="."><plain>Med </plain></SENT>
<SENT sid="7" pm="."><plain>7:350-355, 2001) </plain></SENT>
<SENT sid="8" pm="."><plain>EBNA3C can reverse the ability of Nm23-H1 to suppress migration of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> cell lines in vitro </plain></SENT>
<SENT sid="9" pm="."><plain>EBNA3C contributes to EBV-associated human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> by regulating transcription of a number of cellular and <z:mp ids='MP_0001799'>viral</z:mp> promoters and by targeting and altering the transcription activities of the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> suppressor Nm23-H1 </plain></SENT>
<SENT sid="10" pm="."><plain>Cyclo-oxygenase-2 (COX-2), an inducible enzyme important in <z:mp ids='MP_0001845'>inflammation</z:mp>, is overexpressed in a variety of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and can influence cell migration </plain></SENT>
<SENT sid="11" pm="."><plain>In this report we show that Nm23-H1 and EBNA3C can modulate expression of COX-2 in the context of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> and transformation </plain></SENT>
<SENT sid="12" pm="."><plain>The levels of COX-2 were consistently higher in EBV-positive cells than in EBV-negative cells </plain></SENT>
<SENT sid="13" pm="."><plain>Additionally, we show that Nm23-H1 can upregulate the COX-2 promoter element in luciferase reporter assays, whereas EBNA3C alone did not affect the level of response but clearly contributed to an additive increase when coexpressed with Nm23-H1 </plain></SENT>
<SENT sid="14" pm="."><plain>The downstream effect of COX-2 expression was also evaluated and showed that <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E(2) levels increased with Nm23-H1 and that there was some level of cooperativity in the presence of EBNA3C </plain></SENT>
<SENT sid="15" pm="."><plain>The majority of this response was mediated through the cyclic <z:chebi fb="47" ids="16027,28971">AMP</z:chebi> response element and NF-kappaB sites </plain></SENT>
<SENT sid="16" pm="."><plain>These studies suggest a potential role for COX-2 in EBV-associated human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>